Shao Feng Yu, Maya Michon, Anuradha F Lingappa, Kumar Paulvannan, Dennis Solas, Kim Staats, Justin Ichida, Debendranath Dey, Jeffrey Rosenfeld, Vishwanath R Lingappa
{"title":"An ALS assembly modulator signature in peripheral blood mononuclear cells: implications for ALS pathophysiology, therapeutics, and diagnostics.","authors":"Shao Feng Yu, Maya Michon, Anuradha F Lingappa, Kumar Paulvannan, Dennis Solas, Kim Staats, Justin Ichida, Debendranath Dey, Jeffrey Rosenfeld, Vishwanath R Lingappa","doi":"10.1186/s12014-025-09538-4","DOIUrl":null,"url":null,"abstract":"<p><p>Assembly modulators are a new class of allosteric site-targeted therapeutic small molecules, some of which are effective at restoring nuclear localization of TDP-43 in ALS cellular models, and which display efficacy in a variety of ALS animal models. These compounds have been shown to bind selectively to a small subset of protein disulfide isomerase (PDI), a protein implicated in ALS pathophysiology. The targeted subset of PDI is found within a novel, transient and energy-dependent multi-protein complex that includes other important members of the ALS interactome, such as TDP-43, RanGTPase, and selective autophagy receptor p62/SQSTM1. We demonstrate here that a similar multi-protein complex drug target is present in PBMCs as isolated by energy-dependent drug resin affinity chromatography (eDRAC) and characterized by mass spectrometry and by Western blot (WB). Signature alterations in the composition of the multi-protein complex in PBMCs from ALS patients compared to PBMCs from healthy individuals were identified by WB of eDRAC bound proteins, thereby extending earlier literature suggesting PBMC dysfunction in ALS. Changes in the PBMC drug target in ALS patients compared to healthy individuals include diminished p62/SQSTM1 and appearance of a 17 kDa post-translationally modified form of RanGTPase. These changes are not readily apparent from analysis of whole cell extracts, as the individual protein components within the drug target multi-protein complex comprise only small percentages of the total of those component proteins in the extract. Furthermore, whole blood from ALS patients shows a distinctive degradation of total RanGTPase not observed in blood from healthy individuals. This degradation appears to be rescued by treatment of whole blood from ALS patients for 72 h with ALS-active assembly modulator small molecules. Our findings are consistent with the hypothesis that ALS is fundamentally a disorder of homeostasis that can be detected early, prior to disability, in blood by the methods described, and restored to the healthy state by assembly modulator drug treatment.</p>","PeriodicalId":10468,"journal":{"name":"Clinical proteomics","volume":"22 1","pages":"16"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036218/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12014-025-09538-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Assembly modulators are a new class of allosteric site-targeted therapeutic small molecules, some of which are effective at restoring nuclear localization of TDP-43 in ALS cellular models, and which display efficacy in a variety of ALS animal models. These compounds have been shown to bind selectively to a small subset of protein disulfide isomerase (PDI), a protein implicated in ALS pathophysiology. The targeted subset of PDI is found within a novel, transient and energy-dependent multi-protein complex that includes other important members of the ALS interactome, such as TDP-43, RanGTPase, and selective autophagy receptor p62/SQSTM1. We demonstrate here that a similar multi-protein complex drug target is present in PBMCs as isolated by energy-dependent drug resin affinity chromatography (eDRAC) and characterized by mass spectrometry and by Western blot (WB). Signature alterations in the composition of the multi-protein complex in PBMCs from ALS patients compared to PBMCs from healthy individuals were identified by WB of eDRAC bound proteins, thereby extending earlier literature suggesting PBMC dysfunction in ALS. Changes in the PBMC drug target in ALS patients compared to healthy individuals include diminished p62/SQSTM1 and appearance of a 17 kDa post-translationally modified form of RanGTPase. These changes are not readily apparent from analysis of whole cell extracts, as the individual protein components within the drug target multi-protein complex comprise only small percentages of the total of those component proteins in the extract. Furthermore, whole blood from ALS patients shows a distinctive degradation of total RanGTPase not observed in blood from healthy individuals. This degradation appears to be rescued by treatment of whole blood from ALS patients for 72 h with ALS-active assembly modulator small molecules. Our findings are consistent with the hypothesis that ALS is fundamentally a disorder of homeostasis that can be detected early, prior to disability, in blood by the methods described, and restored to the healthy state by assembly modulator drug treatment.
组装调节剂是一类新的变构位点靶向治疗小分子,其中一些在ALS细胞模型中有效地恢复TDP-43的核定位,并在多种ALS动物模型中显示出疗效。这些化合物已被证明可以选择性地结合蛋白质二硫异构酶(PDI)的一小部分,一种与ALS病理生理有关的蛋白质。PDI的靶向亚群存在于一种新的、瞬时的、能量依赖性的多蛋白复合物中,该复合物包括ALS相互作用组的其他重要成员,如TDP-43、RanGTPase和选择性自噬受体p62/SQSTM1。我们在这里证明了类似的多蛋白复合物药物靶点存在于PBMCs中,该靶点通过能量依赖性药物树脂亲和层析(eDRAC)分离出来,并通过质谱和Western blot (WB)进行了表征。与健康个体的PBMC相比,ALS患者PBMC中多蛋白复合物组成的显著变化通过eDRAC结合蛋白的WB进行了鉴定,从而扩展了早期关于ALS患者PBMC功能障碍的文献。与健康个体相比,ALS患者PBMC药物靶点的变化包括p62/SQSTM1的减少和17 kDa翻译后修饰形式的RanGTPase的出现。这些变化在全细胞提取物的分析中并不明显,因为药物靶标多蛋白复合物中的单个蛋白质成分仅占提取物中这些成分蛋白质总数的一小部分。此外,ALS患者的全血显示出在健康人血液中未观察到的总RanGTPase的明显降解。这种降解似乎可以通过使用ALS活性组装调节剂小分子治疗ALS患者全血72小时来挽救。我们的研究结果与ALS从根本上说是一种体内平衡紊乱的假设是一致的,可以通过上述方法在血液中早期检测到,在残疾之前,并通过组装调节剂药物治疗恢复到健康状态。
期刊介绍:
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.